Discover a new way to find and share stories you'll love… Learn about Reading Desk

All Blogs / Industries / Medical / Pharmaceutical / Popular


Holiday Blogging: Gingersnaps

As I type this, I am eating one of these cookies, so that should be an endorsement. We often make these during the holidays - I found the the recipe online about fifteen years ago (source lost, as you'd figure, even if it's still up somewhere), and it's been a reliable performer. Show More Summary

Holiday Blogging 2014

As of today, posting will be irregular around here until New Year's. I'm not going to disappear entirely (I still have some things backed up to write about), but the holiday season will slow things down. And I promise, as has been the practice here, to post a recipe or two, since cooking is the next thing to chemistry.

AbbVie Competes on Price

Well, folks, if you wonder where the price-cutting competition is in the drug industry, it's here. AbbVie is competing with Gilead in the (very lucrative) hepatitis C market, and since Gilead had already staked out a big position, AbbVie...Show More Summary

Critique of an Ad Seen in "Modern Pharma Guidance" Magazine

The ad shown on the left is the subject of an FDA/OPDP "untitled letter" (definition), which took aim at a Sunovion professional print ad for seizure med Aptiom. According to the FDA reviewer of the ad: “Although Aptiom may reduce seizure...Show More Summary

Merck, Cubist, and Hospira: The Inside

Or as much of the inside as we're likely to have. Thanks to @AndyBiotech on Twitter, here's an SEC document detailing the negotiations between Merck and Cubist. It makes for interesting reading in general - you can see how a deal like...Show More Summary

Weekly Roundup 12.19.14

The holidays have left little time for posting, but here is at least getting in the Weekly Roundup. Hopefully, however, with the respite that is to come, there will be time to build up some editorial content.  In the meantime, … Continue reading ?

Pharma: The Year 2014 in Images

These are my favorite images and posts that appeared in Pharma Marketing Blog in 2014 (see embedded slide deck below - you can also view this directly on slideshare here). It was a very interesting year, especially since FDA finally released some long-awaited social media guidance for the pharma industry. Show More Summary

Another Alzheimer's Antibody Goes Down

The clinical failure rate for disease-modifying Alzheimer's therapies remains perfect, unfortunately: a flat 100%. The latest news is from Roche. Their in-licensed amyloid-targeting antibody (gantenerumab, from MorphoSys) came up empty on an interim trial analysis. Show More Summary

A Holiday Greeting Dance from Drug Channels

Dear Drug Channels reader, Wow. It’s hard to believe that another crazy, busy year is already coming to an end. Thank you for welcoming me into your inboxes and browsers. I’ve had fun writing about 2014’s unexpected, unusual, and fascinating developments. Show More Summary

Nativis In the Clinic

Time to revisit an old favorite around here. Remember Nativis Pharmaceuticals? I do, since they provided one of my most treasured "you can expect legal action" letters. When last mentioned here, they were working on the "Voyager", aShow More Summary

Et Tu, Amgen? Blincyto's Bling! Bling! Price Tag!

FDA approved Amgen's Blincyto (blinatumomab) on December 3, 2014, as a second-line treatment for Philadelphia chromosome-negative precursor B-cell acute lymphoblastic leukemia, which affects around 6,000 patients in the US. The price...Show More Summary

What Would You Put In a Med-Chem Textbook?

I had an interesting note this morning from a reader who's been asked about writing an introductory textbook on medicinal chemistry. He's been looking over the field, and wondering what to include (and what to leave out). Quite a few...Show More Summary

December 2014 news update: Walgreens, Express Scripts, Diplomat, AmerisourceBergen, and CVS Health

December at last! It’s time for our final news roundup of 2015. To help you with the next four nights of Hanukkah, here are four stories that go behind the headlines and highlight notable individuals atop some well-known drug channels...Show More Summary

A letter from PharmedOut

Dear Friends of PharmedOut, Happy Holidays! We hope you saw Pharmed Out quoted in the New York Times last week. We are excited to tell you about our newest vision for PharmedOut in 2015 and beyond, and how you can help. As many of you have noted, silently or vocally, our website and social media presence need an update. Show More Summary

Ben Goldacre writes

Dear Friends Please help us make a real and lasting change. Two years ago I started discussing the problem of withheld trial data with Sense About Science. Back then, the situation seemed hopeless, and I was angry: many institutions were in denial, and many past efforts to fix the problem had ground to a halt. Show More Summary

Pfizer's "Humorous" Menopause Ad Mentions the "V" Word

Pfizer marketers have done it again! First it was an all-female Viagra ad campaign for the treatment of ED (erectile dysfunction; read "Oh Yeah, Baby! Show Me More!... Viagra TV Ads Like This. But Don't Let My FDA See It!"). Now, it's...Show More Summary

Actavis and Namenda

John LaMattina has a column at Forbes about the situation with Actavis and their Alzheimer's drug, Namenda (memantine). That situation is not a pretty one: the company has an extended-release form of the drug coming on, which they believe will be more convenient to dose. Show More Summary

J. Already Known Chem.

A reader sent along this paper, which recently appeared in JACS. He'd read it and was puzzled - not by the content of the paper, but as to "how it got into JACS". So I had a look. It's on the peptide hormone oxyntomodulin, a 37-residue species closely related to glucagon which stimulates insulin release as an agonist at the GLP-1 receptor. Show More Summary

Highlights of CVS Health’s Latest Specialty Market Forecasts

Yesterday, CVS Health held its annual Analyst Day. The accompanying 224-page slide deck provides great insight into the company’s strategy. Senior executives told investors how everything is awesome. There is even a section titled “We...Show More Summary

Copyright © 2011 Regator, LLC